london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Fighting for sight- our story so far

Poster Details

First Author: A.Sarmad UK

Co Author(s):    A. Kumar   N. Din   S. Elsherbiny   P. Stavrou   P.L. Lip   B. Mushtaq   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

Retrospective analysis of visual outcome of patients (Pts) at 4 months, 2 Yrs. & 4 Yrs after treatment with ranibizumab.

Setting:

Tertiary Teaching Hospital

Methods:

Data from Jan 2009 - Dec 2012 analysed. Pts received 3 monthly injections of 0.5 mg Ranibizumab and re-treated PRN. 1567 had 3 loading dose, 1064 & 283 Pts being treated at end of Yr 2 & 4 respectively in tertiary Hospital. Primary outcome was change in LogMAR VA. Re-treatment criterion was retinal thickening on OCT & or loss of VA.

Results:

LogMAR VA after 3rd loading dose showed significant improvement (baseline, 0.63; after 3rd Injection 0.59, p<0.001). Visual outcome at 2 and 4 yrs of treatment are base line 0.61; 2 yr follow-up; 0.67 (p<0.001), 4yr follow-up 0.72, (p>0.5). At 2yr VA in 26% (n=273) unchanged, VA gain of 1-5 letters, 5-10 and >10 letters were 12.21%, 9.58% & 8.44% respectively. VA loss at 2yrs of 1-5 letters, 5-10 & >10 letters were 12.58%, 13.06% & 18.4% respectively. At 4yrs VA unchanged in 31.1% (n=88),VA gain of 1-5 letters, 5-10 & >10 letters were 14.13%, 7.42% & 5.64% respectively. VA loss at 4yrs of 1-5 letters, 5-10 & >10 letters were 15.54%, 14.13% & 12% respectively.

Conclusions:

Pts receiving treatment at 2 yrs, <1/3rd(just under) retained initial VA, while >1/3rd gained VA. At 4 yrs, still 1/3rd retained initial VA and 1/3rd gained VA. This study demonstrates restoration of VA with PRN dosage but continuation of treatment for prolonged periods needed to prevent gradual decline.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy